Eli Lilly and Company

The document provided does not contain any explicit mention of current or future fundraising plans through debt or equity for Eli Lilly. The earnings call discusses financial guidance, revenue updates, investment in R&D, and supply capacity, but no direct statements are made about new fundraising activities. Key financial points include: - Updated revenue guidance to $45.4B-$46B for the year. - Investments in supply, demand creation, and launches. - Other income/expense expected in the range of $325-$425 million expense. - Expected effective tax rate approx. 17%. - EPS guidance ranges provided on reported and non-GAAP basis. - Focus on operational investments funded internally. No details on issuing new debt, equity offerings, or capital raises are found in the available transcript pages.

- Lilly is continuing to scale R&D investments and step up manufacturing and commercial investments to support successful launches of new medicines (Page 3). - Massive investments have been made in parenteral filling capacity and Active Pharmaceutical Ingredient (API) capacity to increase production, a process that can take two to four years (Page 4). - Supply capacity efforts are progressing well, with announced capacities from prior years coming online and accelerating supply growth expected in 2025 (Page 5). - There is a ramp-up planned in demand generation activities within SG&A, reflecting strategic investments to drive growth of late-stage assets moving into phase 2 and phase 3 trials (Page 6). - Lilly is focusing on expanding access internationally and domestically, including improvements in commercial and Medicare access, and expansion into Medicaid programs (Page 5).

- Lilly expects strong revenue growth driven by new products such as Mounjaro, Zepbound, Jaypirca, Kisunla, and Ebglyss. - Guidance includes approximately 50% growth in 4Q revenue, reflecting accelerated demand generation efforts supported by improved supply capacity. - Sequential quarter-over-quarter prescription volumes (TRx and NBRx) for Mounjaro and Zepbound continue to grow strongly, with US volume growth around 35%. - International sales expansion is ongoing, with new country launches for Mounjaro expected to contribute in coming quarters. - Supply constraints have eased, enabling increased shipments and fulfilling back orders, which supports sales acceleration. - Marketing and promotional investments, including increased direct-to-consumer advertising from mid-November 2024 onward, are anticipated to further activate patient demand. - Overall demand is healthy; growth will be supported by both expanding access and ongoing commercial execution into 2025.

- The company expects continued strong revenue growth driven by new products like Mounjaro and Zepbound. - Operating margin expansion is anticipated in the short term despite ramping up investments in SG&A and R&D. - Longer-term operating margins are expected to expand sustainably, justified by increased investments. - Earnings per share (EPS) showed significant improvement in Q3 2024 ($1.19 vs. $0.10 in Q3 2023). - The company foresees a continued acceleration in prescriptions and demand, which will support top-line growth. - Demand generation activities and new market launches will contribute to future growth. - Supply increases will enable meeting growing demand without significant supply constraints. - Pricing is stable with favorable pricing and rebate changes expected to support revenue. - Guidance includes 50% growth expected in Q4 2024, with continued acceleration into 2025.

The provided transcript does not explicitly disclose specific details on Lilly's current or expected orderbook or pending orders. However, relevant points related to demand and supply are: - Demand for key products like Mounjaro and Zepbound is strong with over 25% sequential quarter-on-quarter TRx growth. - Lilly has improved supply constraints significantly, with supply-related customer service calls dropping below 1%. - Supply capacity expansion efforts are progressing well, supporting expected strong growth into 2025. - Inventory dynamics show some lumpiness due to channel stocking but overall consumption is accelerating. - Lilly is cautiously matching demand stimulation activities with supply ramp-up to avoid shortages. - Access to Mounjaro is at 93%, with continued progress in commercial, Medicare, and Medicaid coverage. - New product launches overseas and improved access are expected to drive further demand growth. - The company anticipates more demand generation spending and operating margin expansion in the near term. No quantified orderbook or pending order figures are provided.